Vida Ventures GP III, L.L.C.
CIK: 0001855502
Vida Ventures GP III, L.L.C.'s purchase track record
Vida Ventures GP III, L.L.C. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2025 | LBRX | $5.00M | +13.8% | +52.8% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LBRX | ▼ Sell | Other | 547,648 | — | 9/12/2025 | View on chart |
| LBRX | ▼ Sell | Other | 1,262 | — | 9/12/2025 | View on chart |
| LBRX | ▲ Buy | Open Market | 332,566 | $5.0M | 9/12/2025 | View on chart |
| LBRX | ▲ Buy | Open Market | 767 | $12K | 9/12/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage
LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage. LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.